

Richard Kefford

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12030939/publications.pdf>

Version: 2024-02-01

77
papers

14,136
citations

147801
31
h-index

71685
76
g-index

78
all docs

78
docs citations

78
times ranked

17612
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and Tumor Responses with Lambrolizumab (Anti-“PD-1) in Melanoma. New England Journal of Medicine, 2013, 369, 134-144.	27.0	3,128
2	Survival in BRAF V600“Mutant Advanced Melanoma Treated with Vemurafenib. New England Journal of Medicine, 2012, 366, 707-714.	27.0	1,955
3	Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet, The, 2014, 384, 1109-1117.	13.7	1,588
4	Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma. New England Journal of Medicine, 2017, 377, 1813-1823.	27.0	1,192
5	Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. JAMA - Journal of the American Medical Association, 2016, 315, 1600.	7.4	857
6	Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma. Journal of Clinical Oncology, 2013, 31, 616-622.	1.6	720
7	Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. Journal of Clinical Oncology, 2016, 34, 1510-1517.	1.6	627
8	Programmed Death-Ligand 1 Expression and Response to the Anti-“Programmed Death 1 Antibody Pembrolizumab in Melanoma. Journal of Clinical Oncology, 2016, 34, 4102-4109.	1.6	528
9	Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic <i>BRAF</i>-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor. Journal of Clinical Oncology, 2013, 31, 482-489.	1.6	439
10	Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. Journal of Clinical Oncology, 2018, 36, 1668-1674.	1.6	360
11	Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort. Journal of the American Academy of Dermatology, 2016, 74, 455-461.e1.	1.2	247
12	Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected <i>BRAF</i> V600“Mutant Stage III Melanoma. Journal of Clinical Oncology, 2018, 36, 3441-3449.	1.6	226
13	Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. Clinical Cancer Research, 2018, 24, 4960-4967.	7.0	222
14	Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. Lancet Oncology, The, 2017, 18, 1202-1210.	10.7	211
15	Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer, 2014, 120, 1695-1701.	4.1	195
16	Correlation of <i>BRAF</i> Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials. Clinical Cancer Research, 2016, 22, 567-574.	7.0	185
17	Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436). Clinical Cancer Research, 2013, 19, 4868-4878.	7.0	167
18	Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature.. Journal of Clinical Oncology, 2015, 33, 3001-3001.	1.6	140

#	ARTICLE	IF	CITATIONS
19	Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 358-372.	10.7	94
20	Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanoma. <i>Oncogenesis</i> , 2018, 7, 72.	4.9	69
21	Acneiform eruptions: A common cutaneous toxicity of the MEK inhibitor trametinib. <i>Australasian Journal of Dermatology</i> , 2014, 55, 250-254.	0.7	60
22	Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring—The TADE Study. <i>Clinical Cancer Research</i> , 2016, 22, 3164-3171.	7.0	60
23	Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3005-3005.	1.6	58
24	Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials. <i>Lancet Oncology</i> , The, 2014, 15, 297-304.	10.7	55
25	Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 701-710.	10.7	50
26	Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).. <i>Journal of Clinical Oncology</i> , 2014, 32, LBA9000-LBA9000.	1.6	48
27	Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials. <i>European Journal of Cancer</i> , 2020, 125, 114-120.	2.8	47
28	Updated safety and efficacy results from a phase I/II study of the oral BRAF inhibitor dabrafenib (GSK2118436) combined with the oral MEK 1/2 inhibitor trametinib (GSK1120212) in patients with BRAFi-naïve metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8510-8510.	1.6	41
29	Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapy. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 809-815.e1.	1.2	39
30	Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline <i>CDKN2A</i> mutations. <i>Journal of Medical Genetics</i> , 2020, 57, 316-321.	3.2	33
31	5-year survival outcomes in patients (pts) with advanced melanoma treated with pembrolizumab (pembro) in KEYNOTE-001.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9516-9516.	1.6	32
32	Pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma: Results of the KEYNOTE-029 expansion cohort.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9506-9506.	1.6	30
33	PD-1 and PD-L1 inhibitors in melanoma treatment: past success, present application and future challenges. <i>Immunotherapy</i> , 2016, 8, 733-746.	2.0	28
34	Factors predicting endoxifen levels in breast cancer patients taking standard-dose tamoxifen and following dose escalation.. <i>Journal of Clinical Oncology</i> , 2013, 31, 543-543.	1.6	26
35	Acute Radiation Skin Toxicity Associated With BRAF Inhibitors. <i>Journal of Clinical Oncology</i> , 2016, 34, e17-e20.	1.6	25
36	BREAK-MB: A phase II study assessing overall intracranial response rate (OIRR) to dabrafenib (GSK2118436) in patients (pts) with BRAF V600E/k mutation-positive melanoma with brain metastases (mets).. <i>Journal of Clinical Oncology</i> , 2012, 30, 8501-8501.	1.6	24

#	ARTICLE	IF	CITATIONS
37	Evaluation of immune-related response criteria (irRC) in patients (pts) with advanced melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475.. Journal of Clinical Oncology, 2014, 32, 3006-3006.	1.6	23
38	Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists. Asia-Pacific Journal of Clinical Oncology, 2016, 12, 5-12.	1.1	22
39	Baseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475.. Journal of Clinical Oncology, 2014, 32, 3015-3015.	1.6	22
40	Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).. Journal of Clinical Oncology, 2014, 32, LBA9000-LBA9000.	1.6	22
41	First-in-human, phase I/IIa study of CRLX301, a nanoparticle drug conjugate containing docetaxel, in patients with advanced or metastatic solid malignancies. Investigational New Drugs, 2021, 39, 1047-1056.	2.6	20
42	BRAF inhibitor (BRAFi) dabrafenib in combination with the MEK1/2 inhibitor (MEKi) trametinib in BRAFi-naïve and BRAFi-resistant patients (pts) with BRAF mutation-positive metastatic melanoma (MM).. Journal of Clinical Oncology, 2013, 31, 9005-9005.	1.6	16
43	Atypical patterns of response in patients (pts) with metastatic melanoma treated with pembrolizumab (MK-3475) in KEYNOTE-001.. Journal of Clinical Oncology, 2015, 33, 3000-3000.	1.6	14
44	Updated overall survival (OS) for BR113220, a phase 1-2 study of dabrafenib (D) alone versus combined dabrafenib and trametinib (D+T) in pts with <i>BRAF</i> V600 mutation-positive (+) metastatic melanoma (MM).. Journal of Clinical Oncology, 2014, 32, 9010-9010.	1.6	13
45	Systemic treatments for metastatic cutaneous melanoma. The Cochrane Library, 2014, , .	2.8	12
46	Randomized comparison of two doses of the anti-PD-1 monoclonal antibody MK-3475 for ipilimumab-refractory (IPI-R) and IPI-naïve (IPI-N) melanoma (MEL).. Journal of Clinical Oncology, 2014, 32, 3000-3000.	1.6	11
47	KEYNOTE-029: Efficacy and safety of pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma.. Journal of Clinical Oncology, 2017, 35, 9545-9545.	1.6	10
48	Epirubicin: A phase II study in recurrent small-cell lung cancer. Cancer Chemotherapy and Pharmacology, 1991, 28, 220-222.	2.3	9
49	Treatment Algorithms in Stage IV Melanoma. American Journal of Therapeutics, 2015, 22, 61-67.	0.9	9
50	Association of immune-related thyroid disorders with pembrolizumab (pembro, MK-3475) in patients (pts) with advanced melanoma treated in KEYNOTE-001.. Journal of Clinical Oncology, 2015, 33, 9050-9050.	1.6	9
51	Effect on health-related quality of life (HRQOL) of adjuvant treatment (tx) with dabrafenib plus trametinib (D + T) in patients (pts) with resected stage III <i>BRAF</i>-mutant melanoma.. Journal of Clinical Oncology, 2018, 36, 9590-9590.	1.6	9
52	Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial. Targeted Oncology, 2021, 16, 47-57.	3.6	8
53	Clinical characteristics and survival of BRAF-mutant (BRAF+) metastatic melanoma patients (pts) treated with BRAF inhibitor (BRAFi) dabrafenib or vemurafenib beyond disease progression (PD).. Journal of Clinical Oncology, 2013, 31, 9062-9062.	1.6	8
54	Dabrafenib plus trametinib (D + T) as adjuvant treatment of resected <i>BRAF</i>-mutant stage III melanoma: Findings from the COMBI-AD trial analyzed based on AJCC 8 classification.. Journal of Clinical Oncology, 2018, 36, 9591-9591.	1.6	8

#	ARTICLE	IF	CITATIONS
55	Clinical efficacy and safety of lambrolizumab (MK-3475, Anti-PD-1 monoclonal antibody) in patients with advanced melanoma.. Journal of Clinical Oncology, 2013, 31, 9009-9009.	1.6	7
56	Five-year overall survival (OS) update from a phase II, open-label trial of dabrafenib (D) and trametinib (T) in patients (pts) with <i>BRAF</i> V600â€‘mutant unresectable or metastatic melanoma (MM).. Journal of Clinical Oncology, 2017, 35, 9505-9505.	1.6	7
57	<i>Pneumocystis jirovecii</i> in a patient on doseâ€‘dense chemotherapy for early breast cancer. Respiriology Case Reports, 2019, 7, e00459.	0.6	6
58	A phase II study of the multitargeted kinase inhibitor lenvatinib in patients with advanced BRAF wild-type melanoma.. Journal of Clinical Oncology, 2013, 31, 9026-9026.	1.6	6
59	A phase III trial of nab-paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma: A subanalysis based on BRAF status.. Journal of Clinical Oncology, 2013, 31, 9030-9030.	1.6	6
60	Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors. Targeted Oncology, 2021, 16, 37-46.	3.6	5
61	Comparison of BRAF inhibitor (BRAFi)-induced cutaneous squamous cell carcinoma (cuSCC) and secondary malignancies in BRAF mutation-positive metastatic melanoma (MM) patients (pts) treated with dabrafenib (D) as monotherapy or in combination with MEK1/2 inhibitor (MEKi) trametinib (T).. Journal of Clinical Oncology, 2013, 31, 9016-9016.	1.6	5
62	Updated 5-y landmark analyses of phase 2 (BREAK-2) and phase 3 (BREAK-3) studies evaluating dabrafenib monotherapy in patients with BRAF V600â€‘mutant melanoma.. Journal of Clinical Oncology, 2017, 35, 9526-9526.	1.6	5
63	Model-based analysis of the relationship between pembrolizumab (MK-3475) exposure and efficacy in patients with advanced or metastatic melanoma.. Journal of Clinical Oncology, 2015, 33, 3068-3068.	1.6	4
64	Long-term safety and overall survival update for BREAK-2, a phase 2, single-arm, open-label study of dabrafenib in previously treated metastatic melanoma (NCT01153763).. Journal of Clinical Oncology, 2014, 32, 9034-9034.	1.6	3
65	Final overall survival from a phase 3 trial of nab-paclitaxel versus dacarbazine (DTIC) in chemotherapy-naïve patients with metastatic melanoma.. Journal of Clinical Oncology, 2014, 32, 9045-9045.	1.6	3
66	Lesion-specific patterns of response and progression with anti-PD-1 treatment in metastatic melanoma (MM).. Journal of Clinical Oncology, 2014, 32, 9077-9077.	1.6	3
67	Distinct gene expression, mutational profile and clinical outcomes of V600E and V600K/R BRAF-mutant metastatic melanoma (MM).. Journal of Clinical Oncology, 2017, 35, 9541-9541.	1.6	2
68	Analysis of circulating tumor DNA (ctDNA) in pseudoprogression in anti-PD1 treated metastatic melanoma (MM).. Journal of Clinical Oncology, 2017, 35, 9546-9546.	1.6	2
69	Circulating tumor DNA (ctDNA) in metastatic melanoma (MM) patients (pts) with brain metastases (mets).. Journal of Clinical Oncology, 2019, 37, 9581-9581.	1.6	2
70	Neoadjuvant systemic therapy for breast cancer: the <sc>W</sc>estmead experience. ANZ Journal of Surgery, 2018, 88, 640-644.	0.7	1
71	Reply to E. HindiÃ© and K.R. Hess. Journal of Clinical Oncology, 2019, 37, 1356-1358.	1.6	1
72	Efficacy, safety, and pharmacokinetics (PK) of the BRAF inhibitor dabrafenib (D) hydroxypropyl methylcellulose (HPMC) capsule formulation in combination with the MEK1/2 inhibitor trametinib (T) in patients (pts) with BRAF mutation-positive metastatic melanoma (MM).. Journal of Clinical Oncology, 2013, 31, 9066-9066.	1.6	1

#	ARTICLE	IF	CITATIONS
73	Patterns of acquired resistance to anti-PD-1 antibodies in patients with metastatic melanoma (MM).. Journal of Clinical Oncology, 2015, 33, e20005-e20005.	1.6	1
74	BRAF/MEK inhibition in melanoma patients with rare BRAF mutations.. Journal of Clinical Oncology, 2018, 36, 9542-9542.	1.6	1
75	Circulating tumor DNA (ctDNA) in patients (pts) with metastatic uveal melanoma (UM) treated with protein kinase C inhibitor (PKCi).. Journal of Clinical Oncology, 2020, 38, e22054-e22054.	1.6	1
76	Correlation between pre-existing MEK1P124 mutations and clinical and in vitro response to BRAF inhibitors in metastatic melanoma.. Journal of Clinical Oncology, 2014, 32, 9004-9004.	1.6	0
77	Pharmacokinetic and pharmacodynamic analysis of preoperative therapy with dabrafenib alone and in combination with trametinib in patients with BRAF mutation‐positive melanoma with metastases to the brain (BRV116521).. Journal of Clinical Oncology, 2014, 32, TPS9112-TPS9112.	1.6	0